Request Demo
Last update 08 Nov 2025
S-444823
Last update 08 Nov 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms S 444823, S-444823, S444823 |
Target |
Action agonists |
Mechanism CB1 agonists(Cannabinoid CB1 receptor agonists), CB2 agonists(Cannabinoid CB2 receptor agonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC25H33N3O4S |
InChIKeySYBONVBDFTYUQP-UHFFFAOYSA-N |
CAS Registry885490-15-3 |
Related
1
Clinical Trials associated with S-444823JPRN-jRCT2080220964
A Japanese early phase 2 study of S-444823 ointment in patients with atopic dermatitis
100 Clinical Results associated with S-444823
Login to view more data
100 Translational Medicine associated with S-444823
Login to view more data
100 Patents (Medical) associated with S-444823
Login to view more data
1
Literatures (Medical) associated with S-44482301 Apr 2012Bioorganic & medicinal chemistry lettersQ4 · MEDICINE
Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent
Q4 · MEDICINE
Article
Author: Arimura, Akinori ; Yasui, Kiyoshi ; Odan, Masahide ; Hiramatsu, Yoshiharu ; Ishizuka, Natsuki ; Inagaki, Masanao ; Fujii, Yasuhiko ; Morioka, Yasuhide ; Deguchi, Masashi ; Soga, Masahiko ; Hashizume, Hiroshi ; Mitsumori, Susumu
The optimization of a series of 3-carbamoyl 2-pyridone derivatives as CB agonists is reported. These efforts resulted in the discovery of 3-(2-(1-(cyclohexylmethyl)-2-oxo-1,2,5,6,7,8,9,10-octahydrocycloocta[b]pyridine-3-carboxamido)thiazol-4-yl)propanoic acid (21), a potent dual CB1/CB2 agonist without CNS side effects induced by CB1 receptor activation. It exhibited strong inhibition of scratching as a 1.0% acetone solution in the pruritic model.
100 Deals associated with S-444823
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dermatitis, Atopic | Phase 2 | Japan | - | |
| Pruritus | Discovery | Japan | 01 Apr 2012 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free